Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model.
Krishna
Rajesh
R
Department of Clinical Pharmacology, Merck Research Laboratories, Mailstop RY34-A500, 126 East Lincoln Avenue, Rahway, NJ 07065-0900, USA. rajesh_krishna@merck.com
Wong
Peggy
P
Stevens
Catherine
C
De Lepeleire
Inge
I
Van Dyck
Kristien
K
Rosen
Raymond C
RC
Gendrano
Isaias Noel
IN
Peeters
Mathieu
M
Wagner
John A
JA
Herman
Gary A
GA
D000328:Adult; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology; D011687:Purines / Q000494:pharmacology; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors*; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D010879:Piperazines; D011687:Purines; D044105:Receptor, Melanocortin, Type 4; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate